In conclusion, through the NF-κB and MAPK pathways and histone modification, LTRAs increased IL25, IL33, and TSLP mRNA expression in lung and bronchial epithelial cells, which might provide support for the decreased effectiveness of LTRAs in asthma therapy. The gene discussed is IL25; the disease is asthma.